Efficacy of 5% Minoxidil versus Combined 5% Minoxidil and 0.01% Tretinoin for Male Pattern Hair Loss

2007 ◽  
Vol 8 (5) ◽  
pp. 285-290 ◽  
Author(s):  
Hyo Seung Shin ◽  
Chong Hyun Won ◽  
Seung Ho Lee ◽  
Oh Sang Kwon ◽  
Kyu Han Kim ◽  
...  
Keyword(s):  
Hair Loss ◽  
Male Pattern

Overview and Approach to Medical Management of Male Pattern Hair Loss

2016 ◽  
pp. 79-79
Author(s):  
Samipa Mukherjee ◽  
Madura C ◽  
Chandrashekar BS
Keyword(s):  
Hair Loss ◽  
Medical Management ◽  
Male Pattern

scholarly journals A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity

2020 ◽  
Vol 19 (7) ◽  
pp. 1545-1547 ◽  
Author(s):  
Andy Goren ◽  
Sergio Vaño‐Galván ◽  
Carlos Gustavo Wambier ◽  
John McCoy ◽  
Alba Gomez‐Zubiaur ◽  
...  
Keyword(s):  
Hair Loss ◽  
Preliminary Observation ◽  
Male Pattern

Hormonal treatment for male-pattern hair loss: implications for cancer of the prostate?

2002 ◽  
Vol 90 (7) ◽  
pp. 682-685 ◽  
Author(s):  
W.R. Anderson ◽  
N.M. Harris ◽  
S.A.V. Holmes
Keyword(s):  
Hair Loss ◽  
Hormonal Treatment ◽  
Cancer Of The Prostate ◽  
Male Pattern

Follicular unit transplantation for male-pattern hair loss: Evaluation of 120 patients

2006 ◽  
Vol 59 (11) ◽  
pp. 1162-1169 ◽  
Author(s):  
Nesrin Tan Baser ◽  
Bulent Cigsar ◽  
Unzile Balci Akbuga ◽  
Ahmet Terzioglu ◽  
Gurcan Aslan
Keyword(s):  
Hair Loss ◽  
Follicular Unit ◽  
Male Pattern

Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride

2014 ◽  
Vol 9 (3) ◽  
pp. 222-228 ◽  
Author(s):  
Christine Anne Ganzer ◽  
Alan Roy Jacobs ◽  
Farin Iqbal
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Hair Loss ◽  
Reductase Inhibitor ◽  
Psychological Symptoms ◽  
Physical Symptoms ◽  
Internet Survey ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Male Pattern

Finasteride is a synthetic 5-α reductase inhibitor, which prevents the conversion of testosterone to dihydrotestosterone and has been used for more than 20 years in the treatment of male pattern hair loss. Randomized, controlled trials have associated finasteride with both reversible and persistent adverse effects. In this pilot study, we sought to characterize sexual and nonsexual adverse effects that men reported experiencing at least 3 months after stopping the medication. Based on previous research on persistent side effects of finasteride, we constructed an Internet survey targeting six domains: physical symptoms, sexual libido, ejaculatory disorders, disorders of the penis and testes, cognitive symptoms, and psychological symptoms and was e-mailed to patients who reported experiencing symptoms of side effects of finasteride. Responses from 131 generally healthy men (mean age, 24 years) who had taken finasteride for male pattern hair loss was included in the analysis. The most notable finding was that adverse effects persisted in each of the domains, indicating the possible presence of a “post-finasteride syndrome.”

Hair loss: a clinical update

2019 ◽  
Vol 8 (9) ◽  
pp. 422-429
Author(s):  
Lucy Millar-Hume ◽  
Farah Ali
Keyword(s):  
Hair Loss ◽  
Androgenic Alopecia ◽  
Levels Of Evidence ◽  
Female Pattern Hair Loss ◽  
Male Pattern

Hair loss is classified into non-scarring and scarring alopecias, the latter being further subdivided into primary and secondary forms. These classifications are also referred to as non-cicatricial and cicatricial hair loss. This article focuses on androgenic alopecia (AGA) and will, at times, be referred to as male pattern hair loss (MPHL) or female pattern hair loss (FPHL). Essentially, AGA is a non-scarring, benign form of alopecia, generally related to ageing and where, on the whole, a proportion of hair can grow back. Aestheticians should be prepared to answer a patient's questions and concerns and be familiar with the current levels of evidence surrounding the myriad of treatments available.

Sign in / Sign up

Export Citation Format

Share Document